However, with increasing rates of sedentary behaviors and obesity, it is likely that statins and/or PCSK9 inhibitors would be potential pharmaceutical interventions for the overall pediatric population since the safety profiles of these interventions are not well documented in long-term studies [42]. The gene discussed is PCSK9; the disease is obesity due to melanocortin 4 receptor deficiency.